Ardelyx (ARDX) Gains from Sales and Divestitures (2016 - 2020)
Ardelyx posted quarterly Gains from Sales and Divestitures of $866528.0 for Q4 2020, down 3.72% on a QoQ basis from $900000.0 in Q3 2020.
Ardelyx (ARDX) has 2 years of Gains from Sales and Divestitures data on file, last reported at $866528.0 in Q4 2020.
- For the quarter ending Q4 2020, Gains from Sales and Divestitures changed N/A year-over-year to $866528.0; the trailing twelve-month figure through Dec 2020 stood at $866528.0 (changed N/A YoY), and the FY2020 full-year result was $866528.0, changed N/A from the prior year.
- Gains from Sales and Divestitures for Q4 2020 stood at $866528.0, down from $900000.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $900000.0 in Q3 2020 and bottomed at $5000.0 in Q4 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Ardelyx | 1.48 Bn | 1.25 Bn | 89.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 866,528.00 |
| Dec 31, 2020 | 866,528.00 |
| Sep 30, 2020 | 900,000.00 |
| Sep 30, 2020 | 900,000.00 |
| Dec 31, 2016 | 5,000.00 |
| Dec 31, 2016 | 5,000.00 |